Effects of TIcaGREloR on Circulating Microparticles and Micro-RNAs in patients with Non ST Elevation Acute Coronary Syndromes - TIGER-M study

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI0 个研究点开始时间: 2012年12月28日最近更新: 2016年4月11日

试验速览

暂无简介。

•-PATIENT WITH NON-ST ELEVATION ACUTE CORONARY SYNDROMES - men aged between 50 and 80 years - postmenopausal women
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 24
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 40

•men aged <50 years or >80 years - impossibility to give informed consent - women of childbearing age - diabetes mellitus - severe renal failure (CrCl < 30 ml/min) - infective, neoplastic or autoimmune diseases - ACS and /or TIA/stroke in the previous three months - trauma or surgical operations in the previous three months - active hemorrhage - fibrinolytic therapy within 24 hours before randomization, - a need for oral anticoagulation therapy - an increased risk of bradycardia - drugs study hypersensitivity (including aspirin) - moderate to severe hepatic impairment 15 - co-administration of ticagrelor or clopidogrel with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir)
•GRACE RISK SCORE >140
•In stent restenosis

发起方

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI